XBiotech Inc. (NASDAQ:XBIT) Sees Large Growth in Short Interest

XBiotech Inc. (NASDAQ:XBIT) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 907,400 shares, a growth of 15.2% from the January 15th total of 787,900 shares. Currently, 4.7% of the company’s shares are short sold. Based on an average daily trading volume, of 71,300 shares, the days-to-cover ratio is presently 12.7 days.

Institutional Trading of XBiotech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp increased its position in XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company’s stock valued at $835,000 after purchasing an additional 27,909 shares during the period. Barclays PLC increased its position in XBiotech by 13.9% during the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,661 shares during the period. JPMorgan Chase & Co. increased its position in XBiotech by 68.2% during the 4th quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 5,930 shares during the period. Virtu Financial LLC acquired a new stake in XBiotech during the 4th quarter valued at approximately $58,000. Finally, Bank of New York Mellon Corp increased its position in XBiotech by 7.5% during the 4th quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 6,328 shares during the period. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Price Performance

XBiotech stock opened at $3.27 on Monday. The business has a 50 day moving average of $4.36 and a 200-day moving average of $6.02. XBiotech has a 1 year low of $3.05 and a 1 year high of $9.96. The company has a market capitalization of $99.67 million, a P/E ratio of -3.03 and a beta of 1.45.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.